ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
0/0

Improved GPCR Ligands Based on Genetically Impossible Nanobody-Peptide Fusions

preprint
submitted on 14.08.2019 and posted on 15.08.2019 by Ross Cheloha, Fabian A. Fischer, Andrew W. Woodham, Eileen Daley, Naomi Suminski, Thomas J. Gardella, Hidde L. Ploegh
Here we describe a new method for improving signalling potency and selectivity for suboptimal GPCR ligands through conjugation with receptor-targeting nanobodies

History

Email Address of Submitting Author

ross.cheloha@gmail.com

Institution

Boston Children's Hospital/Harvard Medical School

Country

USA

ORCID For Submitting Author

0000-0001-9871-8333

Declaration of Conflict of Interest

HLP, RWC and TJG have filed a provisional patent covering this work

Exports

Logo branding

Exports